Autolus Therapeutics Announces FDA Approval of AUCATZYL® ( obecabtagene autoleucel - obe-cel ) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia ( r/r B-ALL ) - Autolus Therapeutics ( NASDAQ:AUTL )
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program ( Risk Evaluation Mitigation Strategy ) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
| Ticker |
Sentiment |
Impact |
|
AUTL
|
Neutral
|
4 %
|
|
NHPEF
|
Neutral
|
1 %
|
|
CAH
|
Neutral
|
1 %
|
